leadf
logo-loader
RNS
viewDestiny Pharma PLC

Destiny Pharma PLC - Second Price Monitoring Extn

RNS Number : 2687Y
Destiny Pharma PLC
07 September 2020
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APMBUGDCGSGDGGR

Quick facts: Destiny Pharma PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Destiny Pharma awaits key inflection point mid--2020 in its antimicrobial...

Destiny Pharma (LON:DEST) CEO Neil Clark spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The UK-based, clinical phase biotechnology company is focused on preventing post-surgical infection in a Phase 2b clinical trial with its lead asset. According to its website, Destiny is...

on 01/15/2020

2 min read